Pain intensity on and off levodopa in patients with Parkinson's disease
Identifieur interne : 001672 ( Main/Corpus ); précédent : 001671; suivant : 001673Pain intensity on and off levodopa in patients with Parkinson's disease
Auteurs : Angelika Nebe ; Georg EbersbachSource :
- Movement Disorders [ 0885-3185 ] ; 2009-06-15.
English descriptors
- KwdEn :
Abstract
Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22546
Links to Exploration step
ISTEX:8E0991178F6949A1DE54F0A94995D4063114FFEDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease</title><author><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name><affiliation><mods:affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</mods:affiliation></affiliation></author><author><name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name><affiliation><mods:affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8E0991178F6949A1DE54F0A94995D4063114FFED</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22546</idno><idno type="url">https://api.istex.fr/document/8E0991178F6949A1DE54F0A94995D4063114FFED/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001672</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease</title><author><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name><affiliation><mods:affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</mods:affiliation></affiliation></author><author><name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name><affiliation><mods:affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06-15">2009-06-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1233">1233</biblScope><biblScope unit="page" to="1237">1237</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8E0991178F6949A1DE54F0A94995D4063114FFED</idno><idno type="DOI">10.1002/mds.22546</idno><idno type="ArticleID">MDS22546</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson</term><term>fluctuations</term><term>nonmotor symptoms</term><term>pain</term><term>therapy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Angelika Nebe MD</name><affiliations><json:string>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</json:string></affiliations></json:item><json:item><name>Georg Ebersbach MD</name><affiliations><json:string>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pain</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>fluctuations</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>nonmotor symptoms</value></json:item></subject><articleId><json:string>MDS22546</json:string></articleId><language><json:string>eng</json:string></language><abstract>Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>7.688</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1413</abstractCharCount><pdfWordCount>14082</pdfWordCount><pdfCharCount>92907</pdfCharCount><pdfPageCount>24</pdfPageCount><abstractWordCount>224</abstractWordCount></qualityIndicators><title>Pain intensity on and off levodopa in patients with Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>5</total><last>1237</last><first>1233</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22546</json:string></doi><id>8E0991178F6949A1DE54F0A94995D4063114FFED</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8E0991178F6949A1DE54F0A94995D4063114FFED/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8E0991178F6949A1DE54F0A94995D4063114FFED/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8E0991178F6949A1DE54F0A94995D4063114FFED/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note><note>Boehringer Ingelheim Pharma</note><note>Ipsen Pharma</note><note>Schwarz Pharma (UCB)</note><note>Axxonis Pharma</note><note>Boehringer Ingelheim Pharma</note><note>Cephalon</note><note>Desitin Pharma</note><note>GlaxoSmithKline</note><note>Valeant</note><note>Novartis</note><note>Orion</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease</title><author><persName><forename type="first">Angelika</forename><surname>Nebe</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</affiliation></author><author><persName><forename type="first">Georg</forename><surname>Ebersbach</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Paracelsusring 6a, 14547 Beelitz‐Heilstätten, Germany</p></note><affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1233">1233</biblScope><biblScope unit="page" to="1237">1237</biblScope></imprint></monogr><idno type="istex">8E0991178F6949A1DE54F0A94995D4063114FFED</idno><idno type="DOI">10.1002/mds.22546</idno><idno type="ArticleID">MDS22546</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson</term></item><item><term>pain</term></item><item><term>fluctuations</term></item><item><term>therapy</term></item><item><term>nonmotor symptoms</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-12-20">Received</change><change when="2009-02-22">Registration</change><change when="2009-06-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8E0991178F6949A1DE54F0A94995D4063114FFED/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v24:8</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2009-06-15">15 June 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="20" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22546</doi><idGroup><id type="unit" value="MDS22546"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-12-20"></event><event type="manuscriptRevised" date="2009-02-18"></event><event type="manuscriptAccepted" date="2009-02-22"></event><event type="firstOnline" date="2009-05-01"></event><event type="publishedOnlineFinalForm" date="2009-06-18"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2009-05-01"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1233</numbering><numbering type="pageLast">1237</numbering></numberingGroup><correspondenceTo>Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Paracelsusring 6a, 14547 Beelitz‐Heilstätten, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22546.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="25"></count><count type="wordTotal" number="3056"></count></countGroup><titleGroup><title type="main" xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Pain on and Off Levodopa</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Angelika</givenNames><familyName>Nebe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Georg</givenNames><familyName>Ebersbach</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="ebersbach@parkinson-beelitz.de">ebersbach@parkinson‐beelitz.de</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson</keyword><keyword xml:id="kwd2">pain</keyword><keyword xml:id="kwd3">fluctuations</keyword><keyword xml:id="kwd4">therapy</keyword><keyword xml:id="kwd5">nonmotor symptoms</keyword></keywordGroup><fundingInfo><fundingAgency>Boehringer Ingelheim Pharma</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Ipsen Pharma</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Schwarz Pharma (UCB)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Axxonis Pharma</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Boehringer Ingelheim Pharma</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Cephalon</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Desitin Pharma</fundingAgency></fundingInfo><fundingInfo><fundingAgency>GlaxoSmithKline</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Valeant</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Novartis</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Orion</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (<i>P</i> = 0.001). There was a correlation (<i>P</i> = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Pain intensity on and off levodopa in patients with Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Pain on and Off Levodopa</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pain intensity on and off levodopa in patients with Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Angelika</namePart><namePart type="family">Nebe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Georg</namePart><namePart type="family">Ebersbach</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorder Clinic, Beelitz‐Heilstätten, Germany</affiliation><description>Correspondence: Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Paracelsusring 6a, 14547 Beelitz‐Heilstätten, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-06-15</dateIssued><dateCaptured encoding="w3cdtf">2008-12-20</dateCaptured><dateValid encoding="w3cdtf">2009-02-22</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">25</extent><extent unit="words">3056</extent></physicalDescription><abstract lang="en">Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><note type="funding">Boehringer Ingelheim Pharma</note><note type="funding">Ipsen Pharma</note><note type="funding">Schwarz Pharma (UCB)</note><note type="funding">Axxonis Pharma</note><note type="funding">Boehringer Ingelheim Pharma</note><note type="funding">Cephalon</note><note type="funding">Desitin Pharma</note><note type="funding">GlaxoSmithKline</note><note type="funding">Valeant</note><note type="funding">Novartis</note><note type="funding">Orion</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson</topic><topic>pain</topic><topic>fluctuations</topic><topic>therapy</topic><topic>nonmotor symptoms</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1233</start><end>1237</end><total>5</total></extent></part></relatedItem><identifier type="istex">8E0991178F6949A1DE54F0A94995D4063114FFED</identifier><identifier type="DOI">10.1002/mds.22546</identifier><identifier type="ArticleID">MDS22546</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001672 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001672 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:8E0991178F6949A1DE54F0A94995D4063114FFED
|texte= Pain intensity on and off levodopa in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |